Back to Search
Start Over
A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma
- Source :
- Leukemialymphoma. 53(7)
- Publication Year :
- 2011
-
Abstract
- Bendamustine is approved in the United States for relapsed indolent lymphoma. However, it has not been widely studied in mantle cell lymphoma (MCL). We retrospectively reviewed the records of all patients with MCL who were treated with bendamustine at three centers. The primary endpoint was overall response rate (ORR). Thirty patients with MCL received bendamustine, 25 for relapsed disease. After a median follow-up of 12 months, there were 15 complete responses (CRs) with an ORR of 83% (95% confidence interval [CI] 70-97%). Factors significantly associated with longer survival were achieving a CR and classical (versus blastic) variant of MCL. Grade 3 or 4 neutropenia, anemia and thrombocytopenia occurred in 23%, 3% and 20%, respectively. There was one case of progressive multifocal leukoencephalopathy 10 months after therapy completion. Bendamustine in combination with rituximab demonstrated a high response rate in this study of patients with predominantly relapsed MCL.
- Subjects :
- Oncology
Bendamustine
Adult
Male
Cancer Research
medicine.medical_specialty
Neutropenia
medicine.medical_treatment
Kaplan-Meier Estimate
Lymphoma, Mantle-Cell
Infections
immune system diseases
hemic and lymphatic diseases
Internal medicine
medicine
Clinical endpoint
Bendamustine Hydrochloride
Humans
Antineoplastic Agents, Alkylating
Aged
Retrospective Studies
Aged, 80 and over
Chemotherapy
business.industry
Progressive multifocal leukoencephalopathy
Hematology
Middle Aged
medicine.disease
Thrombocytopenia
Lymphoma
Surgery
Treatment Outcome
Nitrogen Mustard Compounds
Mantle cell lymphoma
Rituximab
Female
business
medicine.drug
Subjects
Details
- ISSN :
- 10292403
- Volume :
- 53
- Issue :
- 7
- Database :
- OpenAIRE
- Journal :
- Leukemialymphoma
- Accession number :
- edsair.doi.dedup.....46f8f328fb81256ef7b740c5fb4bd075